Plerixafor Plus G-CSF Outperforms Chemotherapy in Stem Cell Mobilization

Overview

The PHANTASTIC study demonstrates that first-line plerixafor combined with G-CSF yields higher CD34+ stem cell counts with less toxicity compared to conventional chemotherapy-based mobilization in lymphoma and myeloma patients. This regimen also remains effective in heavily pretreated patients and does not compromise subsequent transplantation outcomes.

Background

Autologous stem cell transplantation (SCT) relies on effective mobilization of hematopoietic stem cells (HSCs) into peripheral blood for collection. Traditional mobilization uses chemotherapy plus G-CSF but is associated with significant toxicity and delayed harvesting. Plerixafor, a CXCR4 antagonist, synergizes with G-CSF to enhance HSC mobilization and has shown superiority over G-CSF alone in phase III trials. However, direct comparisons of plerixafor plus G-CSF versus chemotherapy plus G-CSF as first-line mobilization have been lacking.

Data Highlights

Key Findings

• Plerixafor plus G-CSF mobilizes higher yields of CD34+ stem cells more rapidly than chemotherapy plus G-CSF.
• The combination is associated with significantly less toxicity, including reduced neutropenia and nausea.
• Patients achieve target stem cell collection in fewer apheresis sessions, often within 2 sessions.
• Mobilization with plerixafor plus G-CSF is effective even in heavily pretreated lymphoma and myeloma patients.
• Subsequent transplantation outcomes, including engraftment times and survival, are comparable between the two mobilization strategies.
• The regimen avoids the need for chemotherapy-associated hospitalization and complications.

Clinical Implications

First-line mobilization with plerixafor plus G-CSF should be considered over chemotherapy-based regimens due to superior stem cell yields, reduced toxicity, and comparable transplant outcomes. This approach simplifies the mobilization process, reduces patient morbidity, and may improve resource utilization by minimizing apheresis sessions and hospital stays.

Conclusion

Plerixafor combined with G-CSF offers a safer, more effective first-line stem cell mobilization strategy than chemotherapy plus G-CSF in lymphoma and myeloma patients, supporting its adoption as the preferred mobilization regimen.

References

1. DiPersio et al. 2009 -- Plerixafor and G-CSF for Stem Cell Mobilization in Non-Hodgkin Lymphoma
2. DiPersio et al. 2012 -- Plerixafor and G-CSF for Stem Cell Mobilization in Multiple Myeloma
3. PHANTASTIC Study (NCT01186224) -- Plerixafor Harvesting and No Chemotherapy for Autologous Stem Cell Transplantation